SNIPR receives USD 5.48 million funding from CARB-X to support advancement of CRISPR-medicine SNIPR001 into clinical trials

Press Releases
Written by Christian Mygind

The 1b/2a trial will evaluate SNIPR001 for the prevention of E.coli infections in patients undergoing hematopoietic stem cell transplantation

Press release

Medwatch article (Danish, paywall)

Christian Mygind
Previous

SNIPR receives funding for the development of CRISPR-medicines to improve Environmental Enteric Dysfunction (EED) in pregnant women
Next

Precedential US Federal Court Decision Hands SNIPR a win in patent appeal over Rockefeller University for CRISPR-Cas microbial gene editing